Offering hope for patients with Heart Failure - Results from FINEARTS-HF
Monday, September 2, 2024, 10:00 am UK time // 11:00 CEST
At this event, results from FINEARTS-HF, a Phase III study evaluating the efficacy and safety of finerenone (Kerendia®) versus placebo when added to usual therapy in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) of ≥40%, will be presented. In addition, the results from FINEHEART, an integrated pooled analysis of FINEARTS-HF and the Phase III FIDELIO-DKD and FIGARO-DKD studies, exploring the effects of finerenone on cardio-kidney outcomes in over 19,000 patients with heart failure with a LVEF ≥40% and/or chronic kidney disease (CKD) and type 2 diabetes, are shown and discussed.
Christoph Koenen, Head of Clinical Development & Operations, Bayer Pharmaceuticals, is going to kick off the event with an overview about the disease characteristics of Heart Failure, today’s available therapies and Kerendia’s differentiated structural and pharmacologic profile. Next, Maria Borentain, Head of Cardiovascular and Renal Clinical Development, Bayer Pharmaceuticals, will present the key data of FINEARTS-HF and FINEHEART as well as Kerendia’s ongoing development program. Bernardo Kanahuati, Product Team Lead Kerendia, Bayer Pharmaceuticals, will then put these results into the context of Kerendia’s overall aspiration as an innovative and advanced therapeutic option in Heart Failure and Chronic Kidney Disease and a true cardiorenal brand.
The presentations will be followed by a Q&A session.
